Marketplace®
Every story is an economic story
Donate
Marketplace Tech

Subscribe:

Jun 19, 2018

Will the Theranos scandal put a damper on medical tech investing?

The blood-testing startup Theranos is now firmly in disgrace. Founder Elizabeth Holmes was indicted Friday on federal wire fraud charges and has resigned as the company’s CEO. But whatever happens with Holmes and Theranos, the episode has changed the conversation around biotech investing. Michael Greeley is general partner of Flare Capital Partners in Boston, which specializes in funding health care technology companies. He spoke with Marketplace Tech host Molly Wood about what the Theranos downfall means to the industry overall. (06/19/2018)

Elizabeth Holmes speaks during the closing session of the Clinton Global Initiative 2015 in New York City.
Elizabeth Holmes speaks during the closing session of the Clinton Global Initiative 2015 in New York City.
JP Yim/Getty Images

Subscribe:

Segments From This Episode

The blood-testing startup Theranos is now firmly in disgrace. Founder Elizabeth Holmes was indicted Friday on federal wire fraud charges and has resigned as the company’s CEO. But whatever happens with Holmes and Theranos, the episode has changed the conversation around biotech investing. Michael Greeley is general partner of Flare Capital Partners in Boston, which specializes in funding health care technology companies. He spoke with Marketplace Tech host Molly Wood about what the Theranos downfall means to the industry overall. (06/19/2018)